RTP Mobile Logo
Select Publications

Daver N et al. Efficacy and safety of venetoclax in combination with gilteritinib for relapsed/refractory FLT3-mutated acute myeloid leukemia in the expansion cohort of a phase 1b study. ASH 2020;Abstract 333.

Döhner H et al. Escalated dosing schedules of CC-486 are effective and well tolerated for patients experiencing first acute myeloid leukemia (AML) relapse: Results from the phase III QUAZAR AML-001 maintenance trial. ASH 2020;Abstract 111.

Garcia JS et al. Safety, efficacy, and patient-reported outcomes of venetoclax in combination with azacitidine for the treatment of patients with higher-risk myelodysplastic syndrome: A phase 1b study. ASH 2020;Abstract 656.

Kadia TM et al. Phase II study of CPX-351 plus venetoclax in patients with acute myeloid leukemia (AML). ASH 2020;Abstract 28.

Kadia TM et al. Phase II study of venetoclax added to cladribine + low dose AraC (LDAC) alternating with 5-azacytidine demonstrates high rates of minimal residual disease (MRD) negative complete remissions (CR) and excellent tolerability in older patients with newly diagnosed acute myeloid leukemia. ASH 2020;Abstract 25.

Lachowiez C et al. Interim analysis of the phase 1b/2 study of the BCL-2 inhibitor venetoclax in combination with standard intensive AML induction/consolidation therapy with FLAG-IDA in patients with newly diagnosed or relapsed/refractory AML. ASH 2020;Abstract 332.

Lancet JE et al. Five-year final results of a phase 3 study of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary acute myeloid leukemia (AML): Outcomes by age subgroup and among responders. ASH 2020;Abstract 635.

López Cadenas F et al. Phase 3 study of lenalidomide (LEN) vs placebo in non-transfusion dependent (TD) low risk del(5q) MDS patients  — Interim analysis of the European Sintra-REV trial. ASH 2020;Abstract 536.

Olivia E et al. Health-related quality of life outcomes in patients with myelodysplastic syndromes with ring sideroblasts treated with luspatercept in the MEDALIST study. ASH 2020;Abstract 1611

Paschka P et al. Ivosidenib improves overall survival relative to standard therapies in relapsed or refractory mutant IDH1 AML: Results from matched comparisons to historical controls. ASH 2020;Abstract 625.

Perl AE et al. Clinical outcomes in patients with relapsed/refractory acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib. ASH 2020;Abstract 334.

Pollyea D et al. Results of venetoclax and azacitidine combination in chemotherapy ineligible untreated patients with acute myeloid leukemia with IDH1/2 mutations. ASH 2020;Abstract 461.

Pratz KW et al. A Phase 1 study of gilteritinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed AML: Final results. ASH 2020;Abstract 24.

Pratz KW et al. Delays in time to deterioration of health-related quality of life were observed in patients with acute myeloid leukemia receiving venetoclax in combination with azacitidine or in combination with low-dose cytarabine. ASH 2020;Abstract 589.

Roboz G et al. CC-486 prolongs survival for patients with acute myeloid leukemia in remission after intensive chemotherapy independent of presence of measurable residual disease at study entry: Results from the QUAZAR-AML-001 maintenance trial. ASH 2020;Abstract 692

Sallman DA et al. The first-in-class anti-CD47 antibody magrolimab combined with azacitidine is well-tolerated and effective in AML patients: Phase 1b results. ASH 2020;Abstract 330.

Sekeres MA et al. Efficacy and safety of pevonedistat plus azacitidine vs azacitidine alone in higher-risk myelodysplastic syndromes (MDS) from Study P-2001 (NCT02610777). ASH 2020;Abstract 653.

Stein EM et al. Enasidenib (ENA) monotherapy with addition of azacitidine in non-responders is effective in older patients with newly diagnosed IDH2 mutated acute myeloid leukemia (AML): A completed phase 2/1b sub-study of the Beat AML master trial. ASH 2020;Abstract 636.

Wang ES et al. Phase 3, multicenter, open-label study of gilteritinib, gilteritinib plus azacitidine, or azacitidine alone in newly diagnosed FLT3 mutated (FLT3mut+) acute myeloid leukemia (AML) patients ineligible for intensive induction chemotherapy. ASH 2020;Abstract 27.